Genetically engineered cancer models, but not xenografts, faithfully predict anticancer drug exposure in melanoma tumors

Oncologist

Volumn 17, Issue 10, 2012, Pages 1303-1316

  Combest, Austin J ^a   Roberts, Patrick J ^a   Dillon, Patrick M ^a   Sandison, Katie ^a   Hanna, Suzan K ^a   Ross, Charlene ^a   Habibi, Sohrab ^c   Zamboni, Beth ^g   Müller, Markus ^f   Brunner, Martin ^f   Sharpless, Norman E ^a   Zamboni, William C ^a,b,d,e  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b University of North Carolina   (United States)

^c University of North Carolina at Chapel Hill   (United States)

^d Carolina Center of Cancer Nanotechnology Excellence   (United States)

^e North Carolina Biomedical Innovation Network   (United States)

^f UNIVERSITY OF VIENNA   (Austria)

^g CARLOW UNIVERSITY   (United States)

Author keywords

Carboplatin pharmacokinetics; GEMM; Genetically engineered mouse models; Melanoma models; Microdialysis; Mouse tumor models

Indexed keywords

CARBOPLATIN; PLATINUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CLINICAL ARTICLE; CUTANEOUS MELANOMA; DISEASE MODEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; HUMAN; HUMAN CELL; MALE; MASS SPECTROMETRY; MEAN RESIDENCE TIME; MELANOMA; MICRODIALYSIS; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PLASMA CONCENTRATION-TIME CURVE; PREDICTION; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CELL LINE, TUMOR; HUMANS; MALE; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; SKIN NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84868113123     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0274     Document Type: Article

References (26)

1. Sharpless NE, Depinho RA. The mighty mouse: Genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 2006;5:741-754.
2. Olive KP, Tuveson DA. The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin Cancer Res 2006;12:5277-5287.
3. Politi K, Pao W. How genetically engineered mouse tumor models provide insights into human cancers. J Clin Oncol 2011;29:2273-2281.
4. Singh M, Johnson L. Using genetically engineered mouse models of cancer to aid drug development: An industry perspective. Clin Cancer Res 2006;12:5312-5328.
5. Carretero J, Shimamura T, Rikova K et al. Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell 2010;17:547-559.
6. Engelman JA, Chen L, Tan X et al. Effective use of PI3K andMEKinhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008; 14:1351-1356.
7. Olive KP, Jacobetz MA, Davidson CJ et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324:1457-1461.
8. Singh M, Lima A, Molina R et al. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol 2010; 28:585-593.
9. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001;411:375-379.
10. Mueller MM, Fusenig NE. Friends or foes-bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004;4:839-849.
11. Ruzinova MB, Schoer RA, Gerald W et al. Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell 2003;4:277-289.
12. Sikder H, Huso DL, Zhang H et al. Disruption of Id1 reveals major differences in angiogenesis between transplanted and autochthonous tumors. Cancer Cell 2003;4:291-299.
13. Ojalvo LS, King W, CoxDet al. High-density gene expression analysis of tumor-associated macrophages from mouse mammary tumors. Am J Pathol 2009;174: 1048-1064.
14. Chin L, Pomerantz J, Polsky D et al. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev 1997;11:2822-2834.
15. Sharpless NE, Bardeesy N, Lee KH et al. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 2001;413:86-91.
16. Zamboni WC, Gervais AC, Egorin MJ et al. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother Pharmacol 2004;53:329-336.
17. Morrison JG, White P, McDougall S et al. Validation of a highly sensitive ICP-MS method for the determination of platinum in biofluids: Application to clinical pharmacokinetic studies with oxaliplatin. J Pharm Biomed Anal 2000;24:1-10.
18. Blöchl-Daum B, Müller M, MeisingerVet al. Measurement of extracellular fluid carboplatin kinetics in melanoma metastases with microdialysis. Br J Cancer 1996;73:920-924.
19. Egorin MJ, Van Echo DA, Tipping SJ et al. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res 1984;44: 5432-5438.
20. Erkmen K, Egorin MJ, Reyno LM et al. Effects of storage on the binding of carboplatin to plasma proteins. Cancer Chemother Pharmacol 1995;35:254-256.
21. Mahmood I, Balian JD. The pharmacokinetic principles behind scaling from preclinical results to phase I protocols. Clin Pharmacokinet 1999;36:1-11.
22. Dedrick R, Bischoff KB, Zaharko DS. Interspecies correlation of plasma concentration history of methotrexate (NSC-740). Cancer Chemother Rep 1970;54:95-101.
23. Johansen MJ, Newman RA, Madden T. The use of microdialysis in pharmacokinetics and pharmacodynamics. Pharmacotherapy 1997;17:464-481.
24. Kehr J. A survey on quantitative microdialysis: Theoretical models and practical implications. J Neurosci Methods 1993;48:251-261.
25. Muller M, Schmid R, Georgopoulos A et al. Application of microdialysis to clinical pharmacokinetics in humans. Clin Pharmacol Ther 1995;57:371-380.
26. Muller M, Mader RM, Steiner B et al. 5-fluorouracil kinetics in the interstitial tumor space: Clinical response in breast cancer patients. Cancer Res 1997; 57:2598-2601.